Patent Application: Iron Metabolism Targets for Obesity Treatment

ChangeBridge: Patent Apps - Biotech (C12N)

Published September 24th, 2025

Detected March 27th, 2026

Summary

The USPTO has published a new patent application (US20260085321A1) detailing methods for treating obesity by inhibiting specific iron metabolism genes. The application, filed on September 24, 2025, by inventor Richard Possemato, proposes inducing weight loss through increased lipid catabolism.

View original document View source feed page

What changed

This document is a published patent application from the USPTO, specifically application US20260085321A1, filed on September 24, 2025. It outlines methods for treating obesity and related disorders by inhibiting the expression or function of NFS1, BOLA3, IBA57, or NFU1, or a combination thereof. The proposed mechanism involves inducing a metabolic shift that promotes weight loss by increasing lipid catabolism.

As this is a patent application, it does not impose immediate regulatory obligations or penalties on entities. However, it signals potential future developments in obesity treatment and related intellectual property. Companies involved in pharmaceutical research and development, particularly in metabolic disorders and drug discovery, should be aware of this filing for competitive intelligence and potential licensing opportunities.

Source document (simplified)

← USPTO Patent Applications

IRON METABOLISM TARGETS FOR OBESITY

Application US20260085321A1 Kind: A1 Mar 26, 2026

Inventors

Richard Possemato

Abstract

Provided are methods for promoting weight loss and treating and reducing risk of developing obesity related disorders. The methods involve inhibiting expression or function of NFS1, BOLA3, IBA57, or NFU1, or a combination thereof. The methods induce a metabolic shift that causes weight loss in part by increasing lipid catabolism.